KR20170084688A - Composition for preventing, improving and treating atopic dermatitis comprising ginseng berry extract fermented using Hericium erinaceum mycelium as effective component - Google Patents

Abstract

The fermented product of the ginseng fruit extract fermented by using the mycelia of the present invention has almost no cytotoxicity in comparison with the extract of the ginseng fruit extract and the mushroom mycelium extract. In addition, in the human keratinocyte HaCaT cells, (MDC) and TARC (Thymus and activation regulated chemokine) than the extracts of atopic dermatitis. Therefore, safe functional cosmetics for prevention, improvement or treatment of atopic dermatitis, Food and medicine.

Description

TECHNICAL FIELD The present invention relates to a composition for preventing, ameliorating or treating atopic dermatitis, which contains fermented product of ginseng fruit extract fermented using a mycelium of mushroom mycelium as an active ingredient. as effective component}

The present invention relates to a composition for preventing, ameliorating or treating atopic dermatitis, which comprises a fermented product of a ginseng fruit extract fermented using a mycelium of Aspergillus oryzae as an active ingredient.

Atopic dermatitis is a chronic inflammatory disease that occurs before the development of asthma and allergic diseases. It differs depending on the concentration, quantitative change, or activity level of chemokine. Th2 type of lymphocyte is lesional It also refers to the phenomenon of intrusion into. One of the Th2 chemokines, TARC / CCL17 (thymus and activation-regulated chemokine), is expressed continuously in the thymus and also in keratinocytes. The TARC chemokine plays a role in attracting lymphocytes and is preferentially expressed in Th2 lymphocytes, basophils, and natural killer cells. It is known that MDC / CCL22 (macrophage-derived chemokine) is a chemokine closely related to TARC. MDC / CCL22 is also known to be produced in keratinocyte, and excessive expression of TARC and MDC in serum of patients with atopic dermatitis Feature. In addition, CTACK / CCL27 (cutaneous T cell-attracting chemokine) is a chemokine expressed in the skin and is known to be involved in skin inflammatory diseases. Other manifestations of atopic dermatitis include overexpression of ICAM-1 (intercellular adhesion molecule-1). ICAM-1 acts as a receptor for the lymphocyte surface antigen, And the like.

Atopic dermatitis is an abnormality in the proliferation of keratinocytes due to immunological factors. Exposure of keratinocytes to IFN-γ (interferon-γ) or TNF-α (tumor necrosis factor-α) , MDC, CTACK, and the like are abnormally expressed. This phenomenon is due to increased inflammation and increased penetration of monocytes / T cells into the skin.

It is common to treat atopic dermatitis because it is not easy to find out the source of the dermatitis and it is common to avoid symptom of atopic dermatitis and to control the symptoms of atopic dermatitis by proper treatment. The prescription for atopic dermatitis is mainly medication such as steroids, antihistamines, antibiotics, etc. Steroids (corticosteroids) are highly effective in anti-inflammatory and immunosuppressive actions, , Systemic hormone symptoms, and addictive side effects. Antihistamines help prevent the release of histamine in mast cells, thus alleviating the itchy symptoms, but they are used as a temporary measure. There are side effects such as burning, anxiety and loss of appetite when taken over a long period of time. Accordingly, there is a need for a novel therapeutic composition for atopic dermatitis which is effective for atopic dermatitis but has no side effects.

Ginseng ( Panax ginseng CA Meyer) is a herb that belongs to the genus Ogawa and Ginseng. It has been used in Korea, China and Japan for over 2,000 years and has been used to prevent disease and prolong the life span. The efficacy and effect of ginseng which has been known so far can be determined by the action of the central nervous system, the anticarcinogenic action, the anticancer activity, the immune function regulating action, the anti-diabetic action, the hyperfunction of liver function, the improvement of cardiovascular disorder, Improvement of disorder, effect on osteoporosis, anti-stress, anti-fatigue action, antioxidant activity and anti-aging effect. Ginseng fruit is considered to be more valuable than ginseng since ancient times and has been harvested for the purpose of obtaining seeds. These ginseng fruits are only once in 4th year of ginseng cultivation period, and the yield of ginseng is not much because the yield of ginseng and the quality of ginseng are greatly lowered when the number of seedlings is more than 2 times during the cultivation period. Ginsenoside, a representative physiologically active ingredient of ginseng, is distributed evenly on the ground and underground of ginseng, but ginsenoside of ginseng fruit is reported to have different ginsenoside content and composition than ginseng root.

Korean Patent No. 1382115 discloses a food composition for improving atopic dermatitis containing ginseng fruit extract, and Korean Patent No. 1496557 discloses a composition for prevention or treatment of atopy A pharmaceutical composition is disclosed. However, a composition for preventing, ameliorating, or treating atopic dermatitis containing the fermented product of the ginseng fruit extract fermented by using the mycelia of the present invention as an active ingredient has not yet been disclosed.

According to the present invention, the present invention provides a fermented product of a ginseng fruit extract fermented by using the mycelium of mushrooms, and when the extract is treated with 293T cells as human kidney epithelium, (MDC) and Thymus and activation (TARC) in HaCaT cells, which are human keratinocyte, as compared with the extracts of extracts and mushroom mycelium extracts, regulated chemokine expression was significantly reduced to confirm the synergistic effect, thereby completing the present invention.

In order to solve the above problems, the present invention provides a cosmetic composition for preventing or ameliorating atopic dermatitis containing a fermented product of ginseng fruit extract as an active ingredient.

The present invention also provides a pharmaceutical composition for preventing or treating atopic dermatitis, which comprises a fermented product of a ginseng fruit extract as an active ingredient.

The present invention also provides a health functional food composition for preventing or ameliorating atopic dermatitis comprising a fermented product of a ginseng fruit extract as an active ingredient.

The fermented product of the ginseng fruit extract fermented by using the mycelia of the present invention has almost no cytotoxicity in comparison with the extract of the ginseng fruit extract and the mushroom mycelium extract. In addition, in the human keratinocyte HaCaT cells, (MDC) and TARC (Thymus and activation regulated chemokine) than the extracts of atopic dermatitis. Therefore, safe functional cosmetics for prevention, improvement or treatment of atopic dermatitis, Food and medicine.

FIG. 1 shows the results of comparing ginsenoside contents of the fermented product (JAMI-003) obtained from the phosphoric acid fruit extract fermented with the ginseng fruit extract (JAMI-001) and the mycelia of the mushroom.
FIG. 2 is a graph showing the results of the fermentation (JAMI-003) of the phosphoric acid fruit extract fermented with the extracts of ginseng fruit extract (JAMI-001), mycelium extract of mushroom mushroom (JAMI-002) 293T cells, the cell viability was measured and compared.
FIG. 3 shows the results of RT-PCR (A) and real-time PCR (B) analysis of Marcrophage-derived chemokine (MDC) and TARC (Thymus) in the human keratinocyte HaCaT cells treated with ginseng fruit extract (JAMI- and activation regulated chemokines. Lane 1 is a control group treated with nothing, lane 2 is a control group treated with IFN-γ and TNF-α, lane 3 is IFN-γ, TNF-α and 0.1% ginseng fruit extract (JAMI-001 Lane 4 was treated with IFN-γ, TNF-α and 0.5% JAMI-001 and lane 5 was treated with IFN-γ, TNF-α and 1.0% JAMI-001 , Lane 6 is an experimental group treated with IFN- ?, TNF-? And 5.0% JAMI-001, lane 7 is an experimental group treated with IFN- ?, TNF- ?, and 10% JAMI-001 and GAPDH is a loading control .
FIG. 4 shows the results of RT-PCR (A) and real-time PCR (B) analysis of Marcrophage-derived chemokine (MDC) and TARC (Thymus and activation regulated chemokine). Lane 1 is a control group treated with nothing, lane 2 is a control group treated with IFN-γ and TNF-α, lane 3 is IFN-γ, TNF-α and 0.1% mycelial extract of mycorrhizae (JAMI Lane 4 was treated with IFN-γ, TNF-α and 0.5% JAMI-002 and lane 5 was treated with IFN-γ, TNF-α and 1.0% JAMI-002 Lane 7 is an experimental group treated with IFN-γ, TNF-α and 10% JAMI-002, and GAPDH is an experimental group treated with IFN-γ, TNF-α and 5.0% JAMI- Control.
FIG. 5 shows the results of RT-PCR (A) and real-time PCR (B) when HaCaT cells, which are human keratinocytes, were treated with the fermented product (JAMI-003) ) Analysis of MDC (Marcrophage-derived chemokine) and TARC (Thymus and activation regulated chemokine). Lane 1 is a control group treated with nothing, lane 2 is a control group treated with IFN-γ and TNF-α, lane 3 is a fermentation product of IFN-γ, TNF-α and 0.1% Lane 4 was treated with IFN-γ, TNF-α and 0.5% JAMI-003 and lane 5 was treated with IFN-γ, TNF-α and 1.0% JAMI-003 Lane 7 was an experimental group treated with IFN-γ, TNF-α and 5.0% JAMI-003, lane 7 was an experimental group treated with IFN-γ, TNF-α and 10% JAMI- Loading control.

In order to achieve the object of the present invention, the present invention provides a cosmetic composition for prevention or improvement of atopic dermatitis containing a fermented product of ginseng fruit extract as an active ingredient.

In the cosmetic composition according to one embodiment of the present invention, the fermented product of the ginseng fruit extract may be one prepared by fermenting the ginseng fruit extract with a mycelium of mushroom mushroom, but is not limited thereto.

In addition, the ginseng fruit extract may be a ginseng fruit extract, but is not limited thereto.

In addition, the fermented product of the ginseng fruit extract

1) drying the ginseng fruit by hot air blowing, pulverizing and pulverizing;

2) adding 2 to 7 parts by weight of the ginseng powder to 100 parts by weight of water after the step 1), and extracting the ginseng hot-water extract by hot water extraction at 115 to 135 ° C; And

3) 5 to 15 parts by weight of a culture solution of a mushroom mycorrhizal fungus was inoculated to 100 parts by weight of the hot-water extract of the ginseng fruit obtained in the step 2) and cultured at 20 to 30 ° C for 15 to 25 days to obtain a fermentation product of the ginseng fruit extract And a fermentation product of the ginseng fruit extract obtained from the fermentation method,

Preferably, the fermentation product of the ginseng fruit extract is

1) drying the ginseng fruit by hot air blowing, pulverizing and pulverizing;

2) After the step 1), 5 parts by weight of the ginseng fruit powder is added to 100 parts by weight of water, and the mixture is subjected to hot water extraction at 121 ° C to prepare a ginseng fruit hot water extract; And

3) Inoculating 10 parts by weight of the culture solution of Mushroom mushroom mycelium to 100 parts by weight of the ginseng fruit hot water extract obtained in the step 2) and culturing at 25 ° C for 20 days to obtain a fermented product of the ginseng fruit extract; But may be, but not limited to, a fermentation product of the ginseng fruit extract obtained from the fermentation method.

In addition, the fermented product of the ginseng fruit extract may have increased ginsenoside Re content compared to the ginseng fruit extract, but is not limited thereto.

In addition, the composition may inhibit the expression of MDC (Marcrophage-derived chemokine) and TARC (Thymus and activation regulated chemokine), but the present invention is not limited thereto.

In the cosmetic composition for preventing or improving atopic dermatitis according to the present invention, the cosmetic composition for improving atopic dermatitis may be at least one selected from the group consisting of ointment for external use, cream, softening agent, nutritional lotion, pack, essence, hair tonic, shampoo, Skin lotion, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nutrition lotion, massage cream, nutritional cream, eye cream, moisturizing cream, hand cream, foundation, nutrition essence, sunscreen, But are not limited to, formulations selected from the group consisting of soaps, cleansing foams, cleansing lotions, cleansing creams, body lotions and body cleansers. The composition of each of these formulations may contain various kinds of bases and additives necessary for formulation of the formulation, and the kinds and amounts of these ingredients can be easily selected by those skilled in the art.

When the formulation of the present invention is a paste, cream or gel, animal fibers, plant fibers, wax, paraffin, starch, tracant, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide are used as carrier components .

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.

In the case of the solution or emulsion of the present invention, a solvent, a solvent or an emulsifier is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.

When the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.

When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component is selected from aliphatic alcohol sulfates, aliphatic alcohol ether sulfates, sulfosuccinic acid monoesters, isethionates, imidazolinium derivatives, methyltaurate, sarcosinates, fatty acid amides Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolenic derivatives or ethoxylated glycerol fatty acid esters.

The present invention also provides a pharmaceutical composition for preventing or treating atopic dermatitis, which comprises a fermented product of a ginseng fruit extract as an active ingredient.

The pharmaceutical compositions of the present invention may further comprise suitable carriers, excipients or diluents conventionally used in the manufacture of pharmaceutical compositions.

The pharmaceutical dosage forms of the compositions according to the invention may be used alone or in combination with other pharmaceutically active compounds as well as in a suitable set.

The pharmaceutical composition according to the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions according to a conventional method . Examples of carriers, excipients and diluents that can be contained in the pharmaceutical composition including the fermented product of the ginseng fruit extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, Various compounds including gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, And mixtures thereof. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose or lactose , Gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include withexol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

The preferred dosage of the pharmaceutical composition of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the drug form, the administration route and the period, but can be appropriately selected by those skilled in the art.

The present invention also provides a health functional food composition for preventing or ameliorating atopic dermatitis comprising a fermented product of a ginseng fruit extract as an active ingredient.

The composition may be prepared in any form of powder, granule, ring, tablet, capsule, candy, syrup and beverage, but is not limited thereto.

When the health functional food composition of the present invention is used as a food additive, the health functional food composition may be added as it is, or may be used together with other food or food ingredients, and suitably used according to a conventional method. The active ingredient may be suitably used depending on its intended use (prevention or improvement). Generally, the health functional food composition of the present invention is added in an amount of not more than 15 parts by weight, preferably not more than 10 parts by weight based on the raw material, when the food or beverage is produced. However, in the case of long-term intake intended for health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount of more than the above range.

There is no particular limitation on the kind of the health functional food. Examples of the foods to which the health functional food composition can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen and other noodles, gums, ice cream, soups, Drinks, alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.

In addition, the health functional food composition of the present invention can be produced as a food, particularly a functional food. The functional food of the present invention may contain ingredients that are conventionally added. For example, proteins, carbohydrates, fats, nutrients, and seasonings. For example, in the case of a drink, a natural carbohydrate or a flavoring agent may be included as an additional ingredient in addition to the active ingredient. The natural carbohydrate may be selected from the group consisting of monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose etc.), oligosaccharides, polysaccharides (e.g., dextrin, cyclodextrin, , Xylitol, sorbitol, erythritol, etc.). The flavoring agent may be a natural flavoring agent (e.g., tau Martin, stevia extract, etc.) and a synthetic flavoring agent (e.g., saccharin, aspartame, etc.).

In addition to the above health functional food composition, it is also possible to use various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and its salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, A carbonating agent used in beverages, and the like. Although the ratio of the above-mentioned ingredients is not critical, it is generally selected in the range of 0.01 to 0.1 part by weight based on 100 parts by weight of the health functional food composition of the present invention.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not limited thereto.

Materials and methods

1. Ginseng fruit extract ( JAMI -001) Manufacturing

The concentration of ginseng fruit powder was adjusted to 3% (w / v) and 5% (w / v), hot water was extracted at 121 ℃, and the mixture was cooled at room temperature to 4 ℃ (Ginseng fruit extract is hereinafter referred to as "JAMI-001").

2. Mushroom mushroom  Mycelium extract JAMI -002) Manufacturing

( Hericium erinaceus KACC 42140) was distributed in MCM (Mushroom complete medium) at 25 ℃ and 150 rpm for 20 days at the National Institute of Agricultural Science and Technology , Korea. Using miracloth, Distilled water of the same volume as that of the culture volume was added to the obtained mycelium, and the mixture was subjected to hot water extraction at 121 ° C, cooled at room temperature, filtered with a microracose and stored at 4 ° C (hereinafter, referred to as JAMI-002 Quot;).

3. Mushroom mushroom  Of ginseng fruit extract fermented with mycelium Fermentation product (JAMI-003) manufacture

One) Mushroom mushroom  Cultivation of mycelium

( Hericium erinaceus KACC 42140) was cultivated in MCM (Mushroom complete medium) at 25 ℃ and 150 rpm for 20 days at the National Institute of Agricultural Science and Technology .

2) Fermentation and sterilization of ginseng fruit extract (JAMI-001)

10% (v / v) of mycelia of corn borer was inoculated into the ginseng fruit extract (JAMI-001) and cultured at 25 ° C and 150 rpm for 20 days. The fermented ginseng fruit extract was sterilized at 121 ° C for 10 minutes After cooling at room temperature, the fermented product of sterilized ginseng fruit extract was filtered using Miraclose and stored at 4 ° C. (Fermented product of the ginseng fruit extract fermented with the mycelium of mulberry leaves was referred to as " JAMI-003 ").

4. Analysis of content of ginsenoside

JAMI-001 and its JAMI-003 with 3% and 5% concentration of ginseng fruit powder were respectively extracted with methanol and subjected to LC-MS / MS. As previously reported, the content of ginsenoside Re was significantly higher in the ginseng root than that of the ginseng root by JAMI-001. As shown in Fig. 1, the content of ginsenoside Re was higher in the ginseng root than in the case of Hericium (JAMI-003) showed that the ginsenoside Re content was further increased in the fermented product of the ginseng fruit extract obtained by fermenting the ginseng powder with erinaceus KACC 42140, And the difference between before and after fermentation was larger at 5% than that before fermentation. Therefore, JAMI-003 fermented with JAMI-001 extract having 5% of ginseng fruit powder having the highest ginsenoside Re content effective for skin aging among ginseng saponins was used as a sample of Examples 1 and 2 described below Respectively.

5. Cytotoxicity test

Cytotoxicity was confirmed by using 293T cells, a human kidney epithelial cell line, of the fermented product (JAMI-003) of the fruit extract of phosphorus fermented by using the mycelia of mushroom of the present invention . 293T cells were cultured in DMEM (Dulbeccos Modified Eagle Medium) containing 10% FBS (fetal bovine serum) and cultured in a 37 ° C incubator at 5% CO ₂ Lt; / RTI > In order to confirm the stability of JAMI-003, MTS [3- (4,5-dimethylthiazol-2-yl-5- (3-carboxymethoxyphenyl Cells were plated at 1.5 × 10 ⁴ cells / well in a 96-well plate, and then the cells were cultured in a concentration-dependent manner (0.1%, 0.5% , 1%, 5% and 10%), and cultured for 24 hours at 37 ° C and 5% CO _2. After incubation, MTS solution was added and incubated for 4 hours. The absorbance was measured at 490 nm using a microplate reader and the cell viability was calculated using the following equation.

Cell survival rate (%) = absorbance of the addition group of the sample / absorbance of the control group 100

6. Atopic dermatitis related Chemokine mRNA  Measurement of expression level

      Atopic dermatitis is a complex disease with a variety of pathologies and mechanisms. Pathophysiology is associated with dendritic cell specific T cell lymphocytes, networks of type 1 and type 2 cytokines, and inflammatory chemokines. Macrophage-derived chemokine (MDC / CCL 22) plays a role in supplying Th2 cells to allergic inflammation sites during the pathogenesis of atopic dermatitis. Thymus and activation regulated chemokine (TARC / CCL 17) attract CCR4 + or CCR8 + cells. In the present invention, the amount of mRNA expression of MDC and TARC, which are atopic dermatitis inducing factors that move Th2 cells to the place where allergic inflammation occurs, was measured and the activity of atopic dermatitis was confirmed and used as inflammation index.

MDC and TARC production of the fermented product (JAMI-003), the ginseng fruit extract (JAMI-001) and the mushroom mycelium extract (JAMI-002) of the phosphorus acid fruit extract fermented with the mycelia of the present invention as a sample MRNA expression levels were measured. HaCaT cells, which are human keratinocyte cell lines, were seeded into 6-well plates at 2.5 × 10 ⁵ cells per well. After 24 hours, samples, IFN-γ (50 ng / ml) α (50 ng / ml) and cultured in a 37 ° C. incubator for 12 hours at 5% CO ₂ . The cultured cells were extracted with TRI (TRIzol) reagent, cDNA was synthesized using the extracted total RNA, RT-PCR and real time PCR analysis were performed to confirm the amount of mRNA expression.

Example  One. Mushroom mushroom  Cytotoxicity of fermented product (JAMI-003) of ginseng fruit extract fermented with mycelium

In Example 1, the cytotoxicity of a fermented product (JAMI-003) obtained from ginseng fruit extract fermented using ginseng fruit extract (JAMI-001), mycelium extract of mushroom mycelium (JAMI-002) And compared and analyzed. As a result of confirming the stability of JAMI-001, JAMI-002 and JAMI-003 using 293T cells as normal cells, the fermented product of the ginseng fruit extract fermented by using the mycelia of mushroom mushroom of the present invention JAMI-003) showed no cytotoxicity up to a sample treatment concentration of 10%.

Example  2. Mushroom mushroom  (JAMI-003) treatment of ginseng fruit extract fermented with mycelium of atopic dermatitis Chemokine mRNA  Decreased expression level

The concentration of MDC (Macrophage-derived) according to the treatment concentration of the fermented product (JAMI-003) of ginseng fruit extract (JAMI-001), Ganoderma lucidum mushroom mycelium extract (JAMI-002) chemokine) and TARC (thymus and activation regulated chemokine). As a result, when the extracts of JAMI-001 and JAMI-002 were treated as shown in FIGS. 3 to 5, mRNA expression levels of MDC and TARC were decreased, but MDC And TARC expression were less than about 10% and less than 13 to 49%, respectively (FIGS. 3 and 4). On the other hand, when the fermented product of ginseng fruit extract (JAMI-003) fermented by using mycelia of Aspergillus sp. Marijuana was treated, the amount of mRNA expression of MDC and TARC was remarkably decreased, especially 10% of JAMI-003 The mRNA expression levels of MDC and TARC were reduced by 50.5% and 77.7%, respectively, as compared with the control group treated with IFN-y and TNF-a alone (FIG. 5).

Claims (8)

A cosmetic composition for prevention or improvement of atopic dermatitis containing fermented product of ginseng fruit extract as an active ingredient. [Claim 3] The cosmetic composition for preventing or improving atopic dermatitis according to claim 1, wherein the fermented product of the ginseng fruit extract is prepared by fermenting the extract of Ginseng with the mycelium of mushrooms. The cosmetic composition for preventing or improving atopic dermatitis according to claim 1, wherein the ginseng fruit extract is a ginseng fruit hot water extract. The method according to claim 1, wherein the fermented product of the ginseng fruit extract
1) drying the ginseng fruit by hot air blowing, pulverizing and pulverizing;
2) adding 2 to 7 parts by weight of the ginseng powder to 100 parts by weight of water after the step 1), and extracting the ginseng hot-water extract by hot water extraction at 115 to 135 ° C; And
3) 5 to 15 parts by weight of a culture solution of a mushroom mycorrhizal fungus was inoculated to 100 parts by weight of the hot-water extract of the ginseng fruit obtained in the step 2) and cultured at 20 to 30 ° C for 15 to 25 days to obtain a fermentation product of the ginseng fruit extract Wherein the extract is a fermented product of a ginseng fruit extract obtained from a fermentation method comprising the steps of: The cosmetic composition for preventing or improving atopic dermatitis according to claim 1, wherein the fermented product of the ginseng fruit extract has a higher ginsenoside Re content than the ginseng fruit extract. The cosmetic composition for preventing or improving atopic dermatitis according to claim 1, wherein the composition inhibits the expression of Marcrophage-derived chemokine (MDC) and Thymus and activation regulated chemokine (TARC). A pharmaceutical composition for preventing or treating atopic dermatitis comprising a fermented product of a ginseng fruit extract as an active ingredient. A health functional food composition for prevention or improvement of atopic dermatitis containing fermented product of ginseng fruit extract as an active ingredient.

Images